Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
Derek Alderson(University of Bristol), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Heike I. Grabsch(University of Leeds), Sally Stenning(Medical Research Council), S M Griffin(Unknown), David Cunningham(Royal Marsden NHS Foundation Trust), Matthew Nankivell(MRC Clinical Trials Unit at UCL), A. Crellin(Leeds Teaching Hospitals NHS Trust), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Alicia Okines(Royal Marsden NHS Foundation Trust), Susan Pritchard, Rupert Langer(Johannes Kepler University of Linz), Joyce Thompson(Heartlands Hospital), Richard Krysztopik(Royal United Hospital), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Clare Robb(St George's, University of London), Stephen Falk(At Bristol)
Cited by 223
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k